1YR Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.36M
Enterprise Value€99.54
Total Cash (Recent Filing)€34.90M
Total Debt (Recent Filing)€3.27M
Price to Earnings (P/E)―
Beta105.36
Next Earnings
Nov 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€271.13K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationStrong sensitivity and specificity in the symptomatic high-risk subgroup support the test’s clinical credibility and potential utility in early pancreatic cancer detection. These results can strengthen payer submissions, physician adoption, and the company’s ability to build a durable diagnostic franchise.
Commercial Pipeline GrowthUse across surveillance programs and engagement with leading cancer centers indicate that the product is gaining access to influential clinical customers. A broader pipeline provides a foundation for repeat testing and future volume growth if the company converts interest into routine ordering.
Low Financial LeverageLow debt levels preserve balance-sheet flexibility and avoid the immediate interest and refinancing burden associated with heavily leveraged businesses. This gives management more room to pursue partnerships, financing, and commercial investment while scaling the diagnostic platform.
Bears Say
Persistent Losses And Cash BurnThe company is consuming substantial cash while revenue remains small, showing that current operations do not yet support the cost base. Continued losses can erode equity and require repeated external funding, limiting strategic flexibility until commercial scale and margins improve.
Near-Term Financing NeedA runway extending only into Q4 2026 creates a material execution constraint over the next several quarters. The company must secure financing or strategic capital while expanding sales, and funding terms or delays could restrict investment in clinical and commercial growth.
Adoption Conversion RiskA large engaged pipeline does not yet guarantee recurring test volume because customer workflows and protocols may need to change. Uneven conversion could slow revenue scaling, prolong operating losses, and make the commercial model dependent on a small number of early-adopting centers.
Immunovia AB News
1YR FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is €9.36M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 50 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -€0.003 earnings per share for the quarter, beating the consensus estimate of -€0.004 by <€0.001.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is >-0.01.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -€0.003 in its last earnings report, beating expectations of -€0.004. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in DE:1YR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
1YR Company Deck
1YR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mix of meaningful commercial and clinical progress alongside material operational and financing risks. Key positives include very strong percentage revenue growth, robust clinical performance (83.3% sensitivity, ~92% specificity), major center uptake, and an expanding engaged pipeline. Offsetting these are still-modest absolute revenues, an increased operating loss due to higher personnel and study spending, limited cash runway into Q4 2026 requiring near-term financing or partnerships, and uncertainty around reimbursement levels and timing. Overall, the company is showing clear early commercial and clinical traction but remains exposed to execution and funding risks as it scales.View all DE:1YR earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―